AUSTEDO XR Drug Patent Profile

Which patents cover Austedo Xr, and what generic alternatives are available?

Austedo Xr is a drug marketed by Teva and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-six patent family members in thirty-five countries.

The generic ingredient in AUSTEDO XR is deutetrabenazine. One supplier is listed for this compound. Additional details are available on the deutetrabenazine profile page.

DrugPatentWatch^® Generic Entry Outlook for Austedo Xr

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 3, 2031. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AUSTEDO XR

International Patents:	176
US Patents:	13
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AUSTEDO XR

Paragraph IV (Patent) Challenges for AUSTEDO XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AUSTEDO XR	Extended-release Tablets	deutetrabenazine	6 mg, 12 mg and 24 mg	216354	1	2026-03-02

US Patents and Regulatory Information for AUSTEDO XR

AUSTEDO XR is protected by sixteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-004	May 29, 2024		RX	Yes	No					Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-006	May 29, 2024		RX	Yes	No
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-008	Jul 1, 2024		RX	Yes	No					Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-002	Feb 17, 2023		RX	Yes	No					Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-003	Feb 17, 2023		RX	Yes	No			Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-006	May 29, 2024		RX	Yes	No					Y

International Patents for AUSTEDO XR

When does loss-of-exclusivity occur for AUSTEDO XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Japan

Lithuania

New Zealand

Norway

Poland

Portugal

San Marino

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AUSTEDO XR around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5616345
Canada	3236214
New Zealand	757789	Analogs of deutetrabenazine, their preparation and use
Peru	20191819	ANALOGOS DE DEUTETRABENAZINA, SU PREPARACION Y USO
Portugal	4153136
Eurasian Patent Organization	201791977

Investment Scenario and Fundamentals Analysis for AUSTEDO XR

Last updated: February 20, 2026

What is AUSTEDO XR?

AUSTEDO XR (deutetrabenazine extended-release) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adults. It is the extended-release formulation of AUSTEDO, developed by Teva Pharmaceutical Industries.

Market Overview and Revenue Potential

Current Market Position

• Approval Date: December 2017 (FDA)
• Indications: Huntington's chorea, tardive dyskinesia
• Market Slide: The global neurodegenerative diseases market was valued at approximately $36 billion in 2022 and is projected to grow at a 7% CAGR through 2030 (Fortune Business Insights, 2022).

Addressable Market

Indication	Estimated Patient Population	Market Size (2022 USD)	Growth Rate (2022-2030)
Huntington’s Disease	~30,000 patients in the U.S. (Huntington’s Disease Society of America, 2022)	$200 million*	4-5% annually
Tardive Dyskinesia	Estimated 600,000 in US (American Psychiatric Association, 2021)	$300 million*	5-6% annually

*Market sizes are based on treatment penetration estimates (10-15%) and average annual therapy costs of $15,000 for Huntington’s and $12,000 for tardive dyskinesia.

Competitive Landscape

Major Competitors	Products	Market Share in Indications	Status
Teva	AUSTEDO XR, generic deutetrabenazine	Estimated 60% in US	Leading, preferred
Neurocrine Biosciences	Ingrezza (valbenazine)	30-35%	Second-line
Others	Tetrabenazine, reboxetine	<10%	Niche

Revenue Trends and Outlook

• AUSTEDO XR generated approximately $220 million in U.S. sales in 2022.
• Sales growth driven by expanded FDA labeling and increased awareness.
• Estimated 10-15% annual growth rate over 2023-2026, assuming steady market penetration.

Financial and Developmental Fundamentals

Clinical Data

• Demonstrated efficacy in reducing chorea severity assessed via standardized scales (Total Maximal Chorea Score).
• Good tolerability profile, with adverse effects comparable to older formulations.
• Ongoing trials for additional indications, including pediatric Tourette syndrome and other hyperkinetic movement disorders.

Regulatory and Patent Landscape

• Patent protection until 2030 for AUSTEDO XR formulations.
• Orphan drug designation for Huntington’s disease in some regions offers market exclusivity incentives.
• Pending approval for extended indications could extend revenue streams.

Manufacturing and Supply Chain

• Contract manufacturing has scaled to meet surging demand.
• Supply chain risks are minimized by diversified production facilities.
• Patent disputes with competitors are scarce, reducing legal risks.

Pricing and Reimbursement

• Price: Approximately $15,000 per year per patient in the U.S.
• Favorable reimbursement environment due to FDA approval and label expansion.
• Insurance coverage is widespread, but price sensitivity remains.

Investment Risks and Challenges

• Market penetration hurdles: switching from generic tetrabenazine may slow initial uptake.
• Competitive pressure from neurocrine's Ingrezza and emerging generics.
• Limited pipeline beyond the current indications reduces long-term growth prospects.
• Price pressure and reimbursement constraints could impact margins.

Strategic Considerations

• Focus on expanding indication approvals to sustain growth.
• Partnering with patient advocacy groups could boost adoption.
• Diversification into pediatric and other hyperkinetic movement disorders could unlock new markets.

Key Takeaways

• AUSTEDO XR maintains a solid market position in movement disorder treatments, with revenue growth expected in the near term.
• The drug benefits from patent protections, orphan drug status in certain regions, and a limited competitive landscape.
• Risks include competition from generics and alternative therapies, as well as challenges in expanding market penetration.
• Upside depends on successful regulatory filings, indication expansion, and reimbursement negotiations.

FAQs

1. What are the main competitors of AUSTEDO XR?
   Ingrezza (valbenazine) by Neurocrine Biosciences and tetrabenazine, which is generic, are primary competitors.

2. When are AUSTEDO XR patents set to expire?
   Patent protection extends until 2030 in key markets.

3. What is the approximate market size for Huntington’s chorea?
   Around $200 million in the U.S., with global estimates higher.

4. Does AUSTEDO XR have orphan drug status?
   It has orphan drug designation in select regions, providing exclusivity incentives.

5. What are the main risks for investors?
   Falling behind generics, limited pipeline, competition from newer therapies, and reimbursement pressures.

References

1. Fortune Business Insights. (2022). Neurodegenerative Diseases Market Size, Share and Industry Analysis.
2. Huntington’s Disease Society of America. (2022). Disease prevalence statistics.
3. American Psychiatric Association. (2021). Tardive Dyskinesia epidemiology.
4. U.S. Food and Drug Administration. (2017). FDA approval alert for AUSTEDO XR.
5. Teva Pharmaceuticals. (2023). Annual report 2022.

[1] Fortune Business Insights. (2022). Neurodegenerative Diseases Market Size, Share and Industry Analysis.